Sumatriptan News and Research

RSS
Dr. Reddy reports $257 million revenue from global generics in first-quarter fiscal 2011

Dr. Reddy reports $257 million revenue from global generics in first-quarter fiscal 2011

Zogenix secures $35M financing for commercial launch of SUMAVEL DosePro needle-free delivery system

Zogenix secures $35M financing for commercial launch of SUMAVEL DosePro needle-free delivery system

Par Pharmaceutical reports total revenues of $291.9 million for first-quarter 2010

Par Pharmaceutical reports total revenues of $291.9 million for first-quarter 2010

POZEN enters Settlement Agreement with Teva over generic Treximet ANDA patent infringement litigation

POZEN enters Settlement Agreement with Teva over generic Treximet ANDA patent infringement litigation

52% migraine sufferers found relief from headache with Aspirin: review

52% migraine sufferers found relief from headache with Aspirin: review

Aspirin can reduce acute migraine attacks

Aspirin can reduce acute migraine attacks

Uninsured migraine sufferers likely to get inadequate treatment: Neurology

Uninsured migraine sufferers likely to get inadequate treatment: Neurology

Encouraging results from OptiNose's sumatriptan Phase II study for migraine

Encouraging results from OptiNose's sumatriptan Phase II study for migraine

Aradigm reports net loss of $3.4M for fourth-quarter 2009

Aradigm reports net loss of $3.4M for fourth-quarter 2009

Patheon's first-quarter fiscal 2010 total revenues up 5.2%

Patheon's first-quarter fiscal 2010 total revenues up 5.2%

Survey: Acute migraine therapy would earn 45% patient share in treatment of migraine

Survey: Acute migraine therapy would earn 45% patient share in treatment of migraine

Safeguard Scientifics' aggregate partner company revenue rises 46% in 2009

Safeguard Scientifics' aggregate partner company revenue rises 46% in 2009

POZEN reports net loss of $6.9M for year ended December 31, 2009

POZEN reports net loss of $6.9M for year ended December 31, 2009

Par Pharmaceutical reports total revenues of $1,193.2 million for 2009

Par Pharmaceutical reports total revenues of $1,193.2 million for 2009

Aradigm's first U.S. sale of SUMAVEL DosePro needle-free delivery system triggers $4M milestone payment

Aradigm's first U.S. sale of SUMAVEL DosePro needle-free delivery system triggers $4M milestone payment

Sumavel DosePro and Levadex to earn up to $400M by 2018

Sumavel DosePro and Levadex to earn up to $400M by 2018

Dr. Reddy’s Laboratories reports financial results for third-quarter ended December 31, 2009

Dr. Reddy’s Laboratories reports financial results for third-quarter ended December 31, 2009

Patheon releases the first commercial shipments of SUMAVEL DosePro to Zogenix

Patheon releases the first commercial shipments of SUMAVEL DosePro to Zogenix

High-flow oxygen appears to be more effective in treating cluster headaches

High-flow oxygen appears to be more effective in treating cluster headaches

Zogenix closes its $35M second tranche of Series B preferred stock financing

Zogenix closes its $35M second tranche of Series B preferred stock financing